Ximelagatran for the secondary prevention of venous thromboembolism

Summary

In the randomized, double-blind THRIVE III trial, the oral direct thrombin inhibitor ximelagatran (24 mg twice daily) significantly reduced the incidence of recurrent venous thromboembolism (VTE) versus placebo over 18 months or until premature study drug discontinuation. A complementary follow-up analysis (intention-to-treat) was conducted post-study to evaluate the cumulative risks of locally-confirmed recurrent VTE and death (Kaplan-Meier procedure) over the full 18-month study period, regardless of whether patients discontinued study drug prematurely. Hazard ratios (HRs) between treatments were estimated using Cox proportional hazard modeling. Of 612 and 611 patients receiving ximelagatran and placebo, respectively, 149 and 181 discontinued treatment prematurely. Of these discontinuations, further information could not be collected for 14 and 13patients in the ximelagatran and placebo groups, respectively; among the remaining patients, four VTE events and four deaths occurred in the ximelagatran group, and oneVTE event and five deaths occurred in the placebo group. The resulting cumulative risks of VTE (3.2% vs. 12.7%; HR 0.21; 95% confidence interval [CI], 0.12, 0.36;P < 0.0001) and pulmonary embolism (0.8% vs. 5.2%; HR 0.13; 95% CI 0.04, 0.36;P < 0.0001) were significantly lower in the ximelagatran than in the placebo group over 18 months. Death from any cause over 18 months occurred in 10 and 12 patients, respectively (HR 0.83;95% CI 0.36,1.93;P = 0.7). This complementary follow-up analysis confirms the benefit of oral ximelagatran 24 mg twice daily, administered without coagulation monitoring or dose adjustment, for the long-term secondary prevention of VTE.

Keywords

Oral direct thrombin inhibitor - secondary prevention - THRIVE III - venous thromboembolism - ximelagatran

• References

• 1 Kearon C, Ginsberg JS, Kovacs M J. et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349: 631-9.
• 2 Ridker PM, Goldhaber SZ, Danielson E. et al. Longterm, low intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003; 348: 1425-34.
• 3 Agnelli G, Prandoni P, Santamaria M G. et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 2001; 345: 165-9.
• 4 Schulman S, Granqvist S, Holmström M. et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997; 336: 393-8.
• 5 Levine MN, Raskob G, Beyth R J. et al. Hemorrhagic complications of anticoagulant treatment. Chest 2004; 126 (Suppl. 03) 287S-310S.
• 6 Schulman S, Rhedin A-S, Lindmarker P. et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332: 1661-5.
• 7 Kearon C, Gent M, Hirsh J. et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901-7.
• 8 Büller HR, Agnelli G, Hull RD. et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2004; 126 (Suppl. 03) 401S-28S.
• 9 Eriksson UG, Bredberg U, Gislén K. et al. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur J Clin Pharmacol 2003; 59: 35-43.
• 10 Elg M, Gustafsson D, Carlsson S. Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. Thromb Res 1999; 94: 187-97.
• 11 Eriksson H, Wåhlander K, Gustafsson D. et al. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost 2003; 1: 41-7.
• 12 Sarich TC, Teng R, Peters G R. et al. No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran. Clin Pharmacokinet 2003; 42: 485-92.
• 13 Johansson LC, Frison L, Logren U. et al. Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin Pharmacokinet 2003; 42: 381-92.
• 14 Johansson LC, Andersson M, Fager G. et al. No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers. Clin Pharmacokinet 2003; 42: 475-84.
• 15 Sarich TC, Johansson S, Schützer K-M. et al. The pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor, are unaffected by a single dose of alcohol. J Clin Pharmacol 2004; 44: 388-93.
• 16 Bredberg E, Andersson TB, Frison L. et al. Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug–drug interactions. Clin Pharmacokinet 2003; 42: 765-77.
• 17 Francis CW, Berkowitz SD, Comp P C. et al. Comparison of the oral direct thrombin inhibitor ximelagatran with warfarin for the prevention of venous thromboembolism following total knee replacement: EXULT A. N Engl J Med 2003; 349: 1703-12.
• 18 Eriksson BI, Agnelli G, Cohen A T. et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. The METHRO III study. Thromb Haemost 2003; 89: 288-96.
• 19 Eriksson BI, Agnelli G, Cohen A T. et al. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 2003; 1: 2490-6.
• 20 Colwell CW, Berkowitz SD, Comp P C. et al. Oral direct thrombin inhibitor ximelagatran compared with warfarin for prevention of venous thromboembolism after total knee replacement. J Bone Joint Surg Am.. In press.
• 21 Executive Steering Committee on behalf of the SPORTIF III Investigators.. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003; 362: 1691-8.
• 22 SPORTIF Executive Steering Committee for the SPORTIF V Investigators.. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005; 293: 690-8.
• 23 Wallentin L, Wilcox RG, Weaver W D. et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 2003; 362: 789-97.
• 24 Fiessinger J-N, Huisman MV, Davidson B L. et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized controlled trial. JAMA 2005; 293: 681-9.
• 25 Schulman S, Wåhlander K, Lundström T. et al. Extended secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran for 18 months after 6 months of anticoagulation. N Engl J Med 2003; 349: 1713-21.